ERBB2 and anemia (phenotype): Our findings suggest that carboplatin AUC5 can provide an equivalent cytotoxic effect to carboplatin AUC6 in patients with HER2+ breast cancer receiving six cycles of neoadjuvant treatment consisting of TCHP, with fewer complications associated with clinically significant anaemia.